Encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

In DRAFT guidance, NICE does not recommend encorafenib plus cetuximab for the treatment BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment, as it is not considered cost-effective.

Source:

National Institute for Health and Care Excellence